OMER Healthcare

Omeros Corporation

$18.27+2.47%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 1.3B USD
Enterprise value: 1.1B USD
Full-time employees: 175

Overall health

Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings
Drawback: less profitable than most peersless profitable than peers
Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 2.60 vs a peer median of 0.63)higher risk: bigger price swings (beta 2.60 vs peers 0.63)
Not enough data: growth

Would rank #995 of 1,157 fully scored healthcare companies (bottom 15%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Profitable, but burning cash. Reports a profit, but free cash flow is negative.
Omeros reports a profit but its free cash flow is negative: it spent more on investment and running the business than it brought in. That's common for companies building capacity, but it means the profit isn't yet turning into cash.
Paying shareholders without free cash flow. Paid out $17M over the 3 fiscal years to 2025 with -$191M of free cash flow.
Omeros returned $17M in buybacks and dividends over three fiscal years while its free cash flow totalled -$191M. The money came from its cash pile or from borrowing.
Negative shareholders' equity. Liabilities exceed assets on the balance sheet.
Omeros's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.
Shareholders being diluted. Shares outstanding up 15% from December 2022 to August 2026.
Omeros had 15% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Omeros had 15% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

StockQuotient Score

29/ 100

Oct 5 29 → Nov 4 29

Valuation

Is the price right?

71/100

Moderate▼ 1 since Oct 27 close

3/3 inputs reported · High confidence

Since last year: No major changeValuation also moves with the share price every day.

Why it changed since the Oct 27, 2026 close: Score 72 → 71

Share price +4.5%-1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Stronger than most peers on:

▲ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield9.4%

SEC filings · 12 months to Jun 2026Reported value30% base weight · Z-score 5.38Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-5.8%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-5.2%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield-3.9%

SEC filings · latest balance sheetOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

15/100

Weak

2/3 inputs reported · Partial data

Since last year: No major change

Why

Weaker than most peers on:

▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating marginUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0706 · MAD: 0.1217

Return on assets43.5%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score 2.47Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-288.3%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -16.87Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin38.3%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equityUnavailable

Missing · left out of the scoreInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last year: No major change

Why

Weaker than most peers on:

▼ Beta
▼ Debt / equity
▼ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta2.60

Yahoo Finance · 5-year monthly beta vs the marketOutlier capped at sector 5th/95th percentile33% base weight · Z-score -4.28Sector median: 0.6250 · MAD: 0.3380

Current ratio1.95×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.46Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Shareholders' equity is negative, so debt/equity counts as among the highest in its peer group33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Omeros

Is Omeros getting weaker?: Its latest SEC filing (Aug 12, 2026) showed no major changes. Its overall score is unchanged at 29/100 since Oct 28, 2026.
How is Omeros valued vs its peers?: Priced lower than most peers relative to what it earns. Valuation scores 71/100 against 1,393 healthcare peers. Earnings yield 9.4% vs a peer median of 1.5% (stronger than 93% of peers).Earnings yield 9.4% vs peers 1.5% (stronger than 93% of peers). EBITDA yield -5.8% vs a peer median of 4.0% (weaker than 100% of peers).EBITDA yield -5.8% vs peers 4.0% (weaker than 100% of peers).
Is Omeros growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is Omeros?: Less profitable than most of its peers. Profitability scores 15/100 against 1,393 healthcare peers. Return on assets 43.5% vs a peer median of 1.7% (stronger than 95% of peers).Return on assets 43.5% vs peers 1.7% (stronger than 95% of peers). Return on invested capital -288.3% vs a peer median of 4.7% (weaker than 100% of peers).Return on invested capital -288.3% vs peers 4.7% (weaker than 100% of peers).
How risky is Omeros?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 2.60 vs a peer median of 0.63 (weaker than 100% of peers).Beta 2.60 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Year ended Jun 30, 2026 · filed Aug 12, 2026 · compared with the year ended Sep 30, 2021

No major changes

Worth watching: Omeros is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous year	Latest year	Change
Net income (12 months)	86.2M USD	124.8M USD	+44.9%
Free cash flow (12 months)	−94.8M USD	−68.7M USD	−27.5%
Debt	52.8M USD	73.3M USD	+38.8%
Cash	1.9M USD	2.0M USD	+4.3%
Shares outstanding	72.4M	72.4M	+0.0%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one year at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	—	—	—	—	—	—
Operating margin	—	—	—	—	—	—
Net margin	—	—	—	—	—	—
Return on assets (ROA)	46.3%	8.0%	-31.1%	-56.6%	-1.0%	▲ 56 pts
Return on equity (ROE)	816.8%	55.3%	—	—	—	—
Free cash flow margin	—	—	—	—	—	—
Current ratio	4.79×	3.25×	4.09×	1.69×	2.76×	▲ 64%
Quick ratio	—	—	—	—	—	—
Debt to equity	13.18×	3.68×	—	—	—	—
Interest coverage	-8.83×	-7.20×	-5.33×	-6.77×	-127.91×	▼ >999%

OMER price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings

Drawback: less profitable than most peersless profitable than peers

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 2.60 vs a peer median of 0.63)higher risk: bigger price swings (beta 2.60 vs peers 0.63)

Not enough data: growth

Would rank #995 of 1,157 fully scored healthcare companies (bottom 15%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Profitable, but burning cash. Reports a profit, but free cash flow is negative.

Omeros reports a profit but its free cash flow is negative: it spent more on investment and running the business than it brought in. That's common for companies building capacity, but it means the profit isn't yet turning into cash.

Paying shareholders without free cash flow. Paid out $17M over the 3 fiscal years to 2025 with -$191M of free cash flow.

Omeros returned $17M in buybacks and dividends over three fiscal years while its free cash flow totalled -$191M. The money came from its cash pile or from borrowing.

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.

Omeros's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.

Shareholders being diluted. Shares outstanding up 15% from December 2022 to August 2026.

Omeros had 15% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Omeros had 15% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Questions investors ask about Omeros

Is Omeros getting weaker?

Its latest SEC filing (Aug 12, 2026) showed no major changes. Its overall score is unchanged at 29/100 since Oct 28, 2026.

How is Omeros valued vs its peers?

Priced lower than most peers relative to what it earns. Valuation scores 71/100 against 1,393 healthcare peers. Earnings yield 9.4% vs a peer median of 1.5% (stronger than 93% of peers).Earnings yield 9.4% vs peers 1.5% (stronger than 93% of peers). EBITDA yield -5.8% vs a peer median of 4.0% (weaker than 100% of peers).EBITDA yield -5.8% vs peers 4.0% (weaker than 100% of peers).

Is Omeros growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is Omeros?

Less profitable than most of its peers. Profitability scores 15/100 against 1,393 healthcare peers. Return on assets 43.5% vs a peer median of 1.7% (stronger than 95% of peers).Return on assets 43.5% vs peers 1.7% (stronger than 95% of peers). Return on invested capital -288.3% vs a peer median of 4.7% (weaker than 100% of peers).Return on invested capital -288.3% vs peers 4.7% (weaker than 100% of peers).

How risky is Omeros?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 2.60 vs a peer median of 0.63 (weaker than 100% of peers).Beta 2.60 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Previous year

Latest year

Change

Net income (12 months)

86.2M USD

124.8M USD

+44.9%

Free cash flow (12 months)

−94.8M USD

−68.7M USD

−27.5%

Debt

52.8M USD

73.3M USD

+38.8%

Cash

1.9M USD

2.0M USD

+4.3%

Shares outstanding

72.4M

72.4M

+0.0%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

—

Operating margin

—

Net margin

—

Return on assets (ROA)

46.3%

8.0%

-31.1%

-56.6%

-1.0%

▲ 56 pts

Return on equity (ROE)

816.8%

55.3%

—

Free cash flow margin

—

Current ratio

4.79×

3.25×

4.09×

1.69×

2.76×

▲ 64%

Quick ratio

—

Debt to equity

13.18×

3.68×

—

Interest coverage

-8.83×

-7.20×

-5.33×

-6.77×

-127.91×

▼ >999%